Skip to main content area

COVID-19 – NICE Rapid Guidelines & Evidence Summaries

NICE have updated their collection of COVID-19 Rapid Guidelines & Evidence Summaries – The collection [available HERE with all content relevant to COVID-19] now includes the following:

Details of new & revised Guidelines & Evidence Summaries are included in regular bulletins. Sign up HERE.

NICE Rapid Guidelines & Evidence Summaries are produced using a new process designed for the current emergency – and are developed in collaboration with NHS England and NHS Improvement and a cross-speciality clinical group, supported by the specialist societies and royal colleges. Priority is given to topics that affect people identified as extremely vulnerable from COVID-19 on medical grounds.

The following are in development & due for publication soon:

Planned rapid guidelines

  • Severe chronic obstructive pulmonary disease (COPD).
  • Cystic fibrosis.
  • Dermatological conditions: patients receiving immunosuppression therapy.
  • Myocarditis.
  • Pregnancy complications.
  • Immunosuppressant medicines for gastrointestinal conditions.

Planned rapid evidence summaries

  • Non-steroidal anti-inflammatory drugs.
  • Angiotensin converting enzyme (ACE) inhibitors.